Study of Oral Metronidazole on Postoperative Chemotherapy in Colorectal

Status Recruiting

Clinical Trial Summary

Fusobacterium nucleatum (Fusobacterium nucleatum, Fn) has been identified as an independent risk factor for recurrence of colorectal cancer. In this study, oral metronidazole would be used to reduce the abundance of Fn in patients with high Fn, so as to explore whether oral metronidazole can improve the efficacy of postoperative chemotherapy in patients with colorectal cancer.

Clinical Trial Description

Gut microbiota are linked to chronic inflammation and carcinogenesis. Chemotherapy failure is the major cause of recurrence and poor prognosis in colorectal cancer patients. Previously in the investigators' research, the investigators find the contribution of gut microbiota to chemoresistance in patients with colorectal cancer. The investigators found that Fusobacterium nucleatum (Fn) was abundant in colorectal cancer tissues in patients with recurrence post chemotherapy, and was associated with patient clinicopathological characterisitcs. Furthermore, the investigators' bioinformatic and functional studies demonstrated that Fn promoted colorectal cancer resistance to chemotherapy. Metronidazole has been known to treat with anaerobe infection, including Fusobacterium. So oral metronidazole would be used to reduce the abundance of Fn in patients with high Fn, so as to explore whether oral metronidazole can improve the efficacy of postoperative chemotherapy in patients with colorectal cancer. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04264676
Study type	Interventional
Source	Shanghai Jiao Tong University School of Medicine
Contact	Jingyuan Fang, MD, PhD
Phone	86-021-58752345
Email	jingyuanfang@sjtu.edu.cn
Status	Recruiting
Phase	Phase 2
Start date	March 31, 2020
Completion date	March 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01570452` - Matrilysin Expression in Different Stages of Colorectal Tumors	N/A
Active, not recruiting	`NCT04304209` - Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer	Phase 2
Active, not recruiting	`NCT04398446` - Effect of Hemp-CBD on Patients With CIPN	Phase 2
Recruiting	`NCT04486378` - A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer	Phase 2
Recruiting	`NCT06314958` - Stage II/III Colorectal Cancer Recurrence
Recruiting	`NCT06342440` - Early Detection of Advanced Adenomas and Colorectal Cancer
Recruiting	`NCT04714814` - Mechanisms of Fate Evolution of Colorectal Adenocarcinoma Metastasis
Recruiting	`NCT05898789` - Virtual Rehabilitation for Cancer Survivors	N/A
Completed	`NCT01356264` - Multimodal Prehabilitation for Colorectal Surgery	Phase 2
Recruiting	`NCT04813627` - Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant Chemotherapy
Recruiting	`NCT03448549` - SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients	Phase 3
Recruiting	`NCT03904537` - A Study of Combination of Anti-PD1 Antibody-activated TILs and Chemotherapy in Colorectal Cancer	Phase 1/Phase 2
Not yet recruiting	`NCT05131243` - the Role of ctDNA in Predicting the Recurrence Risk of Colorectal Cancer	N/A
Recruiting	`NCT06076811` - DANISH.MRD: Danish Assessment of Minimal Residual Disease by Liquid Biopsies
Recruiting	`NCT06111105` - Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Colorectal Cancer
Recruiting	`NCT06342401` - Early Onset Colorectal Cancer Detection
Completed	`NCT06271980` - Early-Onset Colorectal Cancer Recurrence

Study of Oral Metronidazole on Postoperative Chemotherapy in Colorectal Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms